MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma-Trial in Progress

被引：14

作者：

Strickler, John H. ^{[1
]}

Nakamura, Yoshiaki ^{[2
]}

Yoshino, Takayuki ^{[3
]}

Catenacci, Daniel V. T. ^{[4
]}

Janjigian, Yelena Y. ^{[5
]}

Barzi, Afsaneh ^{[6
]}

Bekaii-Saab, Tanios S. ^{[7
]}

Lenz, Heinz-Josef ^{[8
]}

Lee, Jeeyun ^{[9
]}

Van Cutsem, Eric ^{[10
,11
]}

Chung, Hyun Cheol ^{[12
]}

Alsina, Maria ^{[13
,14
]}

Siena, Salvatore ^{[15
]}

Mayor, Joal Garrido ^{[16
]}

Palanca-Wessels, Maria Corinna ^{[17
]}

Feng Wentao ^{[17
]}

Marshall, John ^{[18
]}

机构：

[1] Duke Univ, Med Ctr, Durham, NC USA

[2] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan

[3] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[4] Univ Chicago, Med Ctr, Gastrointestinal Oncol Program, Chicago, IL 60637 USA

[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[6] City Hope Comprehens Canc Ctr, Duarte, CA USA

[7] Mayo Clin, Div Hematol Oncol, Phoenix, AZ USA

[8] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA

[9] Sungkyunkwan Univ, Sch Med, Div Hematol Oncol, Dept Med,Samsung Med Ctr, Seoul, South Korea

[10] Univ Hosp Gasthuisberg, Leuven, Belgium

[11] Univ Leuven, Leuven, Belgium

[12] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea

[13] Vall dHebron Univ Hosp, Barcelona, Spain

[14] Inst Oncol VCIO, Barcelona, Spain

[15] Azienda Socio Sanit Terr Niguarda, Milan, Italy

[16] Seattle Genet, Bothell, WA USA

[17] Seattle Genet Inc, Bothell, WA USA

[18] Georgetown Univ, Washington, DC USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期

关键词：

D O I：

10.1200/JCO.2021.39.3_suppl.TPS252

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS252

引用

页数：3

共 50 条

[31] A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)
Kawabata, Ryohei
Izawa, Naoki
Suzuki, Takahisa
Nagahisa, Yoshio
Nishikawa, Kazuhiro
Takahashi, Masazumi
Nakamura, Masato
Ishiguro, Atsushi
Katsuya, Hiroo
Hihara, Jun
Manaka, Dai
Negoro, Yuji
Tsuji, Akihito
Takahashi, Takao
Kochi, Mitsugu
Azuma, Mizutomo
Kadowaki, Shigenori
Michimae, Hirofumi
Sunakawa, Yu
Ichikawa, Wataru
Fujii, Masashi
[J]. TARGETED ONCOLOGY, 2023, 18 (03) : 359 - 368
[32] Characterizing tumor responses from RAINBOW, a randomized phase III trial of ramucirumab (RAM) plus paclitaxel (PAC) vs placebo (PBO) plus PAC in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Bodoky, Gyorgy
Gil-Delgado, Marian
Cascinu, Stefano
Lipatov, Oleg N.
Cunningham, David
Van Cutsem, Eric
Muro, Kei
Chandrawansa, Kumari
Liepa, Astra M.
Carlesi, Roberto
Ohtsu, Atsushi
Wilke, Hansjochen
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[33] Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer
Manish A. Shah
Yoon-Koo Kang
Peter C. Thuss-Patience
Atsushi Ohtsu
Jaffer A. Ajani
Eric Van Cutsem
Silke Hoersch
Marie-Laurence Harle-Yge
Sanne Lysbet de Haas
[J]. Gastric Cancer, 2019, 22 : 803 - 816
[34] Tolerability and quality-of-life (QoL) results from the phase REGARD study: Ramucirumab versus placebo in patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma
Chau, I.
Passalacqua, R.
Zalcberg, J. R.
Fuchs, C. S.
Liepa, A. M.
Hsu, Y.
Schwartz, J. D.
Koshiji, M.
Tabernero, J.
[J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S615 - S615
[35] Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer
Shah, Manish A.
Kang, Yoon-Koo
Thuss-Patience, Peter C.
Ohtsu, Atsushi
Ajani, Jaffer A.
Van Cutsem, Eric
Hoersch, Silke
Harle-Yge, Marie-Laurence
de Haas, Sanne Lysbet
[J]. GASTRIC CANCER, 2019, 22 (04) : 803 - 816
[36] Ramucirumab plus Paclitaxel versus Placebo plus Paclitaxel in Patients with Previously Treated Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma (RAINBOW): A Double-Blind, Randomised Phase 3 Trial
Leitner, H.
[J]. TUMORBOARD, 2015, 4 (01): : 18 - 19
[37] Phase 2 study of trastuzumab deruxtecan in the neoadjuvant treatment for patients with HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003)
Takahari, Daisuke
Kawazoe, Akihito
Machida, Nozomu
Minashi, Keiko
Yamagata, Yukinori
Hara, Hiroki
Wakabayashi, Masashi
Komura, Yu
Sato, Akihiro
Kuwata, Takeshi
Kojima, Motohiro
Shitara, Kohei
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[38] Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Wilke, Hansjochen
Muro, Kei
Van Cutsem, Eric
Oh, Sang-Cheul
Bodoky, Gyoergy
Shimada, Yasuhiro
Hironaka, Shuichi
Sugimoto, Naotoshi
Lipatov, Oleg
Kim, Tae-You
Cunningham, David
Rougier, Philippe
Komatsu, Yoshito
Ajani, Jaffer
Emig, Michael
Carlesi, Roberto
Ferry, David
Chandrawansa, Kumari
Schwartz, Jonathan D.
Ohtsu, Atsushi
[J]. LANCET ONCOLOGY, 2014, 15 (11): : 1224 - 1235
[39] Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial
Tabernero, Josep
Hoff, Paulo M.
Shen, Lin
Ohtsu, Atsushi
Shah, Manish A.
Siddiqui, Asna
Heeson, Sarah
Kiermaier, Astrid
Macharia, Harrison
Restuccia, Eleonora
Kang, Yoon-Koo
[J]. GASTRIC CANCER, 2023, 26 (01) : 123 - 131
[40] Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial
Josep Tabernero
Paulo M. Hoff
Lin Shen
Atsushi Ohtsu
Manish A. Shah
Asna Siddiqui
Sarah Heeson
Astrid Kiermaier
Harrison Macharia
Eleonora Restuccia
Yoon-Koo Kang
[J]. Gastric Cancer, 2023, 26 : 123 - 131

← 1 2 3 4 5 →